A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

  1. Kenneth H. Dinnon
  2. Sarah R. Leist
  3. Alexandra Schäfer
  4. Caitlin E. Edwards
  5. David R. Martinez
  6. Stephanie A. Montgomery
  7. Ande West
  8. Boyd L. Yount
  9. Yixuan J. Hou
  10. Lily E. Adams
  11. Kendra L. Gully
  12. Ariane J. Brown
  13. Emily Huang
  14. Matthew D. Bryant
  15. Ingrid C. Choong
  16. Jeffrey S. Glenn
  17. Lisa E. Gralinski
  18. Timothy P. Sheahan
  19. Ralph S. Baric

Reviewed by

Read the full article

Listed in

Log in to save this article

Abstract

No abstract available

Article activity feed

  1. Version published to 10.1038/s41586-020-2708-8
  2. ScreenIT

    SciScore for 10.1101/2020.05.06.081497: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Human tracheobronchial epithelial cells provided by Dr. Scott Randell were obtained from airway specimens resected from patients undergoing surgery under University of North Carolina Institutional Review Board-approved protocols (#03-1396) by the Cystic Fibrosis Center Tissue Culture Core.
    IACUC: All animal work was approved by Institutional Animal Care and Use Committee at University of North Carolina at Chapel Hill under protocol 19-168 according to guidelines outlined by the Association for the Assessment and Accreditation of Laboratory Animal Care and the U.S. Department of Agriculture.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Serial sections were stained with hematoxylin and eosin, and stained for immunohistochemistry for SARS-CoV-2 nucleocapsid using a monoclonal anti-SARS-CoV-1 nucleocapsid antibody (NB100-56576, Novus Biologicals) on deparaffinized sections on the Ventana Discovery Ultra platform (Roche).
    anti-SARS-CoV-1
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Vero E6 cells were maintained in n Dulbecco’s modified Eagle’s medium (DMEM; Gibco), 5% Fetal Clone II serum (FCII, Hyclone), and 1X antibiotic/antimycotic (Gibco).
    Vero E6
    suggested: RRID:CVCL_XD71)
    Experimental Models: Organisms/Strains
    SentencesResources
    BALB/c mice were obtained from Envigo (strain 047).
    BALB/c
    suggested: None
    Software and Algorithms
    SentencesResources
    Structure modelling was performed using Modeller (Version 9.20) and visualized using PyMOL (Version 1.8.6.0).
    Modeller
    suggested: (MODELLER, RRID:SCR_008395)
    PyMOL
    suggested: (PyMOL, RRID:SCR_000305)
    Pegylated-IFN-λ1 treatment in vitro and in vivo: Peginterferon Lambda-1a was obtained from Eiger BioPharmaceuticals by MTA in GMP prefilled syringes, 0.18 mg/syringe (0.4 mg/mL).
    Eiger BioPharmaceuticals
    suggested: None
    Photomicrographs were captured on an Olympus BX43 light microscope at 200X magnification with a DP27 camera using cellSens Dimension software.
    cellSens
    suggested: None
    Data analysis and presentation: All data visualize and analyzed in Prism (version 8.4.2).
    Prism
    suggested: (PRISM, RRID:SCR_005375)
    Figures arranged in Adobe Illustrator (version 24.1).
    Adobe Illustrator
    suggested: (Adobe Illustrator, RRID:SCR_010279)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: We found the following clinical trial numbers in your paper:

    IdentifierStatusTitle
    NCT04331899Active, not recruitingSingle-Blind Study of a Single Dose of Peginterferon Lambda-…
    NCT04343976Enrolling by invitationPegylated Interferon Lambda Treatment for COVID-19
    NCT04344600RecruitingPeginterferon Lambda-1a for the Prevention and Treatment of …
    NCT04354259RecruitingInterferon Lambda for Immediate Antiviral Therapy at Diagnos…

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.05.06.081497v1 on bioRxiv